<DOC>
	<DOCNO>NCT00444561</DOCNO>
	<brief_summary>This exploratory study design evaluate various pharmacodynamic effect subcutaneously ( SC ) infuse injected pramlintide obese , nondiabetic male postmenopausal female ( hormone replacement therapy ) subject . The study also assess safety tolerability pramlintide administer SC infusion injection .</brief_summary>
	<brief_title>Exploratory Study Evaluate Various Pharmacodynamic Effects Subcutaneously Infused Injected Pramlintide Obese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Pramlintide</mesh_term>
	<mesh_term>Islet Amyloid Polypeptide</mesh_term>
	<criteria>Is &lt; 6 ' 3 '' ( 190.5 cm ) tall weigh &lt; 300 lb ( ~136.3 kg ) Is obese body mass index ( BMI ) &gt; =30 kg/m^2 &lt; =45 kg/m^2 history consistent progressive weight gain development obesity secondary drastic traumatic initiating event ( e.g. , excessive weight gain due cessation smoking ) Is nonsmoker ( never smoke smoke least 2 year ) Does clinical diagnosis diabetes Has major change daily physical activity within 2 month prior study start ( e.g. , initiation exercise program ) Usually consume three major meal ( morning , midday , even ) day rarely ( less week ) wake eat night Is currently enrol weight loss program plan enroll weight loss exercise program within next 3 month Is currently treat expect require undergo treatment treat within 2 month screen medication exclude : Over counter antiobesity agent include herbal supplement prescription antiobesity agent approve longterm ( include orlistat [ Xenical ] sibutramine [ Meridia ] ) shortterm ( include phentermine [ AdipexP , Celltech , ProFast SA , ProFast SR , Fastin , Oby trim , Zantryl , Teramine , Phentride , Phentercot , Obephen , Obycap ] , mazindol [ Sanorex Mazanor ] , methamphetamine [ Desoxyn ] , diethylpropion [ Tenuate Tenuate Dospan ] , phendimetrazine [ Bontril , Prelu2 , Melfiat 105 , Unicelles , XTrozine , Plegine , Adipost , Obezine , Phendiet105 , PT 105 ] benzphetamine [ Didrex ] ) treatment obesity Systemic steroids oral , intravenous , intramuscular route potent topical steroid know result high systemic absorption Alpha BetaBlockers , centrally act sympathicolytic sympathicomimetic agent , reserpin , guanethidine , etc . Psychotropic medication ( e.g. , tricyclic antidepressant , monoamine oxidase [ MAO ] inhibitor , selective serotonin reuptake inhibitor [ SSRIs ] , neuroleptic , lithium , benzodiazepine ) Hypnoticsedative medication medication may affect sleep behavior include medication contain caffeine Drugs directly affect gastrointestinal motility , include limited : metoclopramide ( Reglan® ) cisapride ( Propulsid® ) ; macrolide antibiotic erythromycin new derivative Has receive investigational drug within 3 month study start Has participate previously study use pramlintide</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>pramlintide</keyword>
	<keyword>Symlin</keyword>
	<keyword>Amylin</keyword>
</DOC>